Clinical Trials

Enrolling Trials

1-10  of  132
39039039STM4001, Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Treatment of Side Effects
Adult
The primary efficacy objective of this study is to investigate whether rivaroxaban is superior to placebo in reducing the cumulative incidence of DVT, PE, and VTE-related death in adult subjects with various cancer types who are scheduled to receive systemic cancer therapy, and are at high risk of developing a VTE as measured by the cumulative incidence of objectively confirmed: 1) symptomatic lower extremity DVT, upper extremity DVT, and non-fatal PE; 2) asymptomatic proximal DVT of the lower extremities and incidental PE; and 3) VTE-related death occurring from randomization to Day 180.
4941L, National Wilms Tumor Late Effects Study
McManus, Michael J
Late Effects - Wilms
Child
The objectives of the study are to determine the incidence of life-threatening medical conditions in survivors of Wilms tumor, specifically a) congestive heart failure; b) second malignant neoplasms (SMNs); c) renal failure, and d) pulmonary fibrosis and interstitial lung disease. To relate the risks of these events to the type and amount of radiation and chemotherapy received. To determine mortality rates in former Wilms tumor patients and to compare these with age, calendar period, and sex-specific national population rates. To determine the risks of serious pregnancy complications and other adverse reproductive events in survivors of Wilms tumor, and to correlate their occurrence with the type and amount of radiation and chemotherapy received in childhood. To determine the rates and natality in former Wilms tumor patients and to compare these with national statistics and determne congenital anomalies in offspring. To determine the frequency of Wilms tumor and other cancers in the children and other family members of Wilms tumor patients. Specifically, a) to estimate the recurrence risk in siblings and offspring; and b) to identify familial cancer syndromes that may involve Wilms tumor patients. To serve as a case-finding resource, identifying the most informative subgroups ofWilms tumor patients for use by a) molecular biologists studying mutations in identified or prospective Wilms tumor genes including genes fomilial Wilms tumor; and b) epidemiologists studying parental occupational exposures and other environmental risk factors.
Carpenter, Bonnie M
(715) 389-3639
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
McManus, Michael J
Other Blood Cancers - ALL - Acute Lymphocyctic
Child
This pilot trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and myeloid/lymphoid or mixed-lineage leukemia (MLL) gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
McManus, Michael J
Blood - ALL - Acute Lymphocyctic
Child
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells.
Welter, Stacy L
(715) 221-6492
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
McManus, Michael J
Brain, Spinal Cord - Spinal Cord
Child, Adult
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Onitilo, Adedayo A
Lung
Adult
LUNG-MAP SUB-STUDY
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid
McManus, Michael J
Blood - Other
Child
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by either killing the cells, by stopping them from dividing, or by stopping them from spreading. Completely removing or reducing the amount of anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an effective treatment for acute promyelocytic leukemia and may reduce some of the long-term side effects.
Welter, Stacy L
(715) 221-6492
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
Onitilo, Adedayo A
Treatment of Side Effects
Stomach, Intestine, Gut - Rectum
Breast
Lung
Adult
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony stimulating factor may help doctors use colony stimulating factor when it is needed.
Spindler, Toshia J
(715) 221-6495
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Randomised, Double-blind, Parallel group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Gayle, Arlene A
Breast
Adult
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
Revels, Cheryl M
(715) 389-4177
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Evans, Anthony C, Jr.
Ovaries, Uterus, Cervix - Cervix
Adult
This randomized phase II trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with triapine in treating cervical or vaginal cancer.
Revels, Cheryl M
(715) 389-4177
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,